Supervised Injectable Opioid Agonist Treatment

05/09/2026

Oral and injectable opioid agonist treatments for people who use street opioids: a systematic literature review and network meta-analysis
Nick Bansback et al. BMC Public Health. 2025.

« Diacetylmorphine plus oral methadone was associated with a smaller proportion of participation in criminalized activities relative to methadone alone.

Conclusion: Both diacetylmorphine and injectable hydromorphone supplemented with methadone showed favourable retention compared to methadone and buprenorphine, depending on the strength of the OAT being co-prescribed or being compared to. These results provide further support for alternatives to conventional OATs such as diacetylmorphine or injectable hydromorphone for treatment retention. »

Both diacetylmorphine and injectable hydromorphone supplemented with methadone showed favourable retention compared to methadone and buprenorphine, depending on the strength of the OAT being co-prescribed or being compared to. These results provide further support for alternatives to conventional OA...

03/13/2026

Memories of Oslo, Norway

03/03/2026

Thank you! Twenty years of delivering patient centered care and innovation!!

02/25/2026

3 decades of experience with inhaled opioid agonist treatment in the Netherlands. An RCT, safety & efficacy back in 2003. You might ask how many have access to this care in British Columbia? None?

https://www.bmj.com/content/327/7410/310

02/25/2026

02/20/2026

“Many mistake the hopelessness of the drug war with failed enforcement, rather than the persistent demand for drugs. But nearly all of its harms arise—and increase—with successful enforcement of the policy path we have chosen,” says Cato Institute President and CEO Peter Goettler.

https://ow.ly/1GfW50YhIWR

02/13/2026

Presented at HAT expert meeting January 28-29, Oslo, Norway.

https://health-infobase.canada.ca/substance-related-harms/opioids-stimulants/maps.html

02/12/2026

Presented at HAT expert meeting January 28-29, Oslo, Norway. Some countries have oral, injectable, intranasal & inhalable formulations.

02/11/2026

Expanding access to take-home HAT aligns with human rights-based healthcare and uplifts economic, social, and cultural rights of people who need this care. Inclusive of oral, injectable, intranasal and inhalable formulations. Presented at HAT expert meeting January 28-29, Oslo, Norway.

02/03/2026

Supervised injectable opioid agonist treatment is established as standard care and one aspect of a comprehensive treatment framework. From Professor Wim van den Brink presentation at Heroin-assisted treatment expert meeting January 28-29, Oslo, Norway.